- Home
- FISV vs RPRX Comparison
FISV vs RPRX Comparison
Compare FISV & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FISV | RPRX |
|---|---|---|
| Founded | 1984 | 1996 |
| Country | United States | United States |
| Employees | 38000 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 25.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FISV | RPRX |
|---|---|---|
| Price | $52.31 | $58.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 5 |
| Target Price | ★ $146.17 | $51.40 |
| AVG Volume (30 Days) | ★ 6.2M | 2.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.67 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | N/A | $38.63 |
| Revenue Next Year | $3.94 | $4.73 |
| P/E Ratio | ★ $9.94 | $87.81 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $47.04 | $34.63 |
| 52 Week High | $70.41 | $59.72 |
Technical Indicators
Market Signals| Indicator | FISV | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.62 | 60.72 |
| Support Level | $52.54 | $54.95 |
| Resistance Level | $55.36 | N/A |
| Average True Range (ATR) | 1.57 | 1.29 |
| MACD | 0.26 | 0.07 |
| Stochastic Oscillator | 99.36 | 83.02 |
Price Performance
Historical ComparisonAbout FISV Fiserv Inc.
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Following its 2019 merger with First Data, Fiserv also provides payment processing services to merchants. About 10% of the company's revenue is generated internationally.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.